A commentary by Mark Feinberg, M.D., Ph.D., IAVI president and CEO
Features
IAVI’s Dr. Jayanta Bhattacharya, of the Translational Health Science and Technology Institute, India, is interviewed by DBT/Wellcome Trust India All...
May 21, 2021
IAVI remembers Dr. Deepak Gaur, Deputy Country Director, India, and extends our deepest sympathies to his family.
May 19, 2021
This HIV Vaccine Awareness Day, we join the call for women to be at the center of the HIV response to lead their own solutions.
Scientists and community liaisons highlight the importance of collaboration in achieving an affordable, globally accessible HIV vaccine.
April 10, 2021
A spate of news coverage on the results of the Phase I IAVI G001 HIV vaccine clinical trial reflects current public interest in vaccine development ...
April 2, 2021
IAVI recognizes the Government of India for their unwavering support of the development of safe, effective, accessible, preventive HIV vaccines and bi...
March 29, 2021
Failure to meet commitments for TB research is not inevitable; the global COVID-19 response may show us the way.
IAVI CEO Mark Feinberg charts future HIV-1 vaccine development efforts in NEJM.
Results illuminate potential way forward for use of broadly neutralizing antibodies to prevent HIV
March 12, 2021
IAVI and partners recently held a webinar on challenges and opportunities for R&D of innovative biomedical treatments for COVID-19.
Show More
Media Contacts
North America
Rose Catlos
+1 212 847 1049
RCatlos@iavi.org
